drugset / Trial / NCT01371994

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

NCT01371994

Phase 4 Completed 640 enrolled Astellas Pharma Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of solifenacin succinate versus placebo in participants who are incontinent after Robotic Assisted Radical Prostatectomy. This study will also assess the effect of 12 weeks of treatment with solifenacin succinate versus placebo on quality of life (QOL) as measured by questionnaires.

Timeline

Start
2011-08-02
Primary completion
2013-10-21
Completion
2013-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule 5 mg Oral
Subject Solifenacin Small molecule 10 mg Oral

Indications

No indication recorded.